LIS
ARQT icon

Legacy Investment Solutions’s Arcutis Biotherapeutics ARQT Stock Holding History

Legacy Investment Solutions’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$5.05K Buy
+360
New +$5.05K ﹤0.01% 398
2024
Q4 		$4.18K Hold
360
– – ﹤0.01% 410
2024
Q3 		$3.77K Buy
+360
New +$3.55K ﹤0.01% 419

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Legacy Investment Solutions's ARQT Position: Q2 2025 in Review

Legacy Investment Solutions opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2025: 360 shares worth $5.05K. The stake represents ﹤0.01% of the portfolio and ranks #398 among its holdings. This is a return to the name: Legacy Investment Solutions previously reported a position in ARQT as recently as Q4 2024.

Legacy Investment Solutions first reported a position in ARQT in Q3 2024 and has held it in 3 quarters since. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

  • Legacy Investment Solutions held 360 shares of Arcutis Biotherapeutics worth $5.05K as of Q2 2025.
  • Arcutis Biotherapeutics was a new Legacy Investment Solutions position in Q2 2025.
  • Arcutis Biotherapeutics made up ﹤0.01% of Legacy Investment Solutions's portfolio in Q2 2025, its #398 holding.
  • Legacy Investment Solutions first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 3 quarters since.
  • 230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Legacy Investment Solutions's 13F filing for Q2 2025, filed 6 Aug 2025.